Avidity Biosciences

Inactive

RNAM (NGM)

Avidity Biosciences, Inc. is a biopharmaceutical company developing RNA therapeutics called antibody oligonucleotide conjugates (AOCs). The platform links monoclonal antibody specificity with RNA precision to target diseases previously untreatable with RNA medicines. Its pipeline includes Delpacibart zotadirsen for Duchenne muscular dystrophy (Phase 2 EXPLORE44), Delpacibart etedesiran for myotonic dystrophy type 1 (Phase 3), and Delpacibart braxlosiran for FSHD (Phase 1/2). It also pursues precision cardiology candidates AOC 1086 and AOC 1072. Founded 2012 in San Diego; as of Feb 27, 2026, a Novartis subsidiary.